Thompson Siegel & Walmsley’s Aurinia Pharmaceuticals AUPH Stock Holding History

Thompson Siegel & Walmsley’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-18,000	Closed	-$412K	–	635
2021 Q4	$412K	Buy	18,000 +8,000	+80%	+$190K	0.01%	324
2021 Q3	$221K	Sell	10,000 -40,000	-80%	-$635K	﹤0.01%	364
2021 Q2	$648K	Buy	50,000 +19,000	+61%	+$242K	0.01%	299
2021 Q1	$403K	Buy	31,000 +16,000	+107%	+$232K	0.01%	309
2020 Q4	$207K	Buy	+15,000	New	+$218K	﹤0.01%	335

Other funds holding AUPH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Thompson Siegel & Walmsley's AUPH Position: Q1 2022 in Review

Thompson Siegel & Walmsley sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2022, closing a stake of 18,000 shares — an estimated $412K sold.

Thompson Siegel & Walmsley first reported a position in AUPH in Q4 2020 and held it in 5 quarters. The position peaked at $648K in Q2 2021. 184 funds tracked by Wall St. Rank hold AUPH as of Q1 2022.

Thompson Siegel & Walmsley reported no remaining Aurinia Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Thompson Siegel & Walmsley sold 18,000 Aurinia Pharmaceuticals shares in Q1 2022, an estimated $412K.
Thompson Siegel & Walmsley first reported a position in Aurinia Pharmaceuticals in Q4 2020 and held it in 5 quarters.
Thompson Siegel & Walmsley's Aurinia Pharmaceuticals position peaked at $648K in Q2 2021.
184 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2022.

Based on Thompson Siegel & Walmsley's 13F filing for Q1 2022, filed 26 Apr 2022.